The Protective Effects of Bevacizumab in Bleomycin-Induced Experimental Scleroderma

Koca, Süleyman Serdar; Özgen, Metin; Dağlı, Adile Ferda; Gözel, Nevzat; Ozercan, İbrahim Hanifi; Işık, Ahmet Turan

doi:10.17219/acem/32484

Cited by 8 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…it is a disease in which hardening of skin and connective tissue occurs either locally or all over the body. In scleroderma, scleroderma has been classified into localized and systemic [14]. Despite of the details of its pathogenesis remain unclear, its characteristics are pro-inflammatory cytokines, autoimmunity, and high levels of autoantibodies contribute to micro-vascular damage, inflammation, and fibrosis [2,15].…”

Section: Discussionmentioning

confidence: 99%

Analysis on the Effect of Early Screening and Safe Management of Dysphagia in Scleroderma Patients

Huang¹,

Wen²,

Huang³

et al. 2020

AJNS

View full text Add to dashboard Cite

Objective: To analyze the effect of early screening and safe management of dysphagia in scleroderma patients.Methods: From January 2016 to January 2020, a randomized controlled trial was performed with scleroderma patients (n = 42) who were diagnosed as scleroderma. In intervention group, the participants are accepted early screening and safe management of swallowing disorders. The participants of control group are accepted common nursing service. Result: the 48.84% of participants have problems in swallowing process, most participants provide assessment of level 2 of WST. In swallowing test assessment, more participants think they feel obstruction when eating steamed bread. The accident aspiration pneumonia has higher risk than that of aspiration pneumonia in two group (10.00% vs 3.75% & 37.50% vs 23.75%). In research of swallowing function treatment, most participants of intervention group are basic recovery in treatment outcome, the control group have most invalid assessment in treatment outcome. Conclusion: the early screening and safe management of dysphagia can efficacy improve scleroderma dysphagia of scleroderma patients. In dysphagia problem, the scleroderma patients have higher risk of accident aspiration, and the early screening and safe management of dysphagia can improve problems of accident aspiration and aspiration pneumonia. Additionally, the early screening and safe management of dysphagia have strong effect for dysphagia.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis on the Effect of Early Screening and Safe Management of Dysphagia in Scleroderma Patients

Huang¹,

Wen²,

Huang³

et al. 2020

AJNS

View full text Add to dashboard Cite

show abstract

“…50 Consistently, neutralizing of all isoforms of VEGF-A by the humanized monoclonal antibody bevacizumab ameliorated hepatic fibrosis induced by CCl 4 in rats 51 and attenuated bleomycin-induced skin fibrosis. 52 Several VEGF inhibitors are currently evaluated in for the treatment of various types of cancer. Studies of bevacizumab have entered phase II clinical trial for the treatment of pulmonary fibrosis.…”

Section: Vascular Endothelial Growth Factormentioning

confidence: 99%

Therapeutic molecular targets of SSc-ILD

Zhang

Distler

2020

Journal of Scleroderma and Related Disorders

View full text Add to dashboard Cite

Systemic sclerosis is a fibrosing chronic connective tissue disease of unknown etiology. A major hallmark of systemic sclerosis is the uncontrolled and persistent activation of fibroblasts, which release excessive amounts of extracellular matrix, lead to organ dysfunction, and cause high mobility and motility of patients. Systemic sclerosis–associated interstitial lung disease is one of the most common fibrotic organ manifestations in systemic sclerosis and a major cause of death. Treatment options for systemic sclerosis–associated interstitial lung disease and other fibrotic manifestations, however, remain very limited. Thus, there is a huge medical need for effective therapies that target tissue fibrosis, vascular alterations, inflammation, and autoimmune disease in systemic sclerosis–associated interstitial lung disease. In this review, we discuss data suggesting therapeutic ways to target different genes in distinct tissues/organs that contribute to the development of SSc.

show abstract

“…The reduction of capillary density consequently leads to an impairment in the supply of oxygen and nutrients and thus to a hypoxic state. In this situation, angiogenesis is usually triggered but in SSc the vascular recovery is profoundly disturbed and then impaired and the loss of angiogenesis with avascular areas becomes eventually a prominent event [20–22]. …”

Section: Introductionmentioning

confidence: 99%

“…In this perspective, the choice of a vasoactive therapeutic strategy aiming at the modulation, in the “time” frame of each phase of microvascular involvement, of the angiogenic process might be a pivotal event changing the approach to SSc therapy in diffuse or limited SSc. In the future, targeting the early inflammatory pro-angiogenic process [22] leading to capillary aberration might be a relevant step to block the disease evolution to prevent the loss of angiogenesis.…”

Section: Introductionmentioning

confidence: 99%

The “myth” of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event?

et al. 2017

View full text Add to dashboard Cite

Systemic sclerosis is considered a disease dominated by a “loss of angiogenesis”, although in its early phases evidence indicates a disturbed angiogenic response only. In fact, microvascular changes are primarily due to endothelial cell injury, triggering downstream significant enlargement of the capillary in an inflammatory environment, followed by capillary rupture (microhemorrhages). Subsequent pro-angiogenic efforts lead to an aberrant angiogenesis and, eventually, to a total loss of vessel repair and regeneration (loss of angiogenesis). This clearly suggests that the pathogenetic process has a steady progression: from an early excessive pro-angiogenesis, to an aberrant microvascular regeneration, then ending with a late loss of angiogenesis. Herein, we suggest the loss of angiogenesis should not be considered as an overall “myth” characterizing systemic sclerosis but as a very late event of the vascular pathogenesis. Future research should be oriented essentially on the earlier phases dominated by excessive pro-angiogenesis and microvascular aberration.

show abstract

The Protective Effects of Bevacizumab in Bleomycin-Induced Experimental Scleroderma

Cited by 8 publications

References 16 publications

Analysis on the Effect of Early Screening and Safe Management of Dysphagia in Scleroderma Patients

Analysis on the Effect of Early Screening and Safe Management of Dysphagia in Scleroderma Patients

Therapeutic molecular targets of SSc-ILD

The “myth” of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event?

Contact Info

Product

Resources

About